Ziprasidone + Sertraline + Haloperidol
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Affective Disorders
Conditions
Affective Disorders
Trial Timeline
Apr 1, 2003 → Aug 1, 2005
NCT ID
NCT00340379About Ziprasidone + Sertraline + Haloperidol
Ziprasidone + Sertraline + Haloperidol is a phase 2/3 stage product being developed by Pfizer for Affective Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00340379. Target conditions include Affective Disorders.
What happened to similar drugs?
2 of 8 similar drugs in Affective Disorders were approved
Approved (2) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00340379 | Phase 2/3 | Completed |
Competing Products
14 competing products in Affective Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Haloperidol + Olanzapine | Eli Lilly | Approved | 43 |
| Lurasidone HCl | Sumitomo Pharma | Phase 1 | 29 |
| Paliperidone ER | Johnson & Johnson | Phase 3 | 40 |
| Placebo + Paliperidone ER + Paliperidone ER | Johnson & Johnson | Phase 3 | 40 |
| Paliperidone ER + Paliperidone ER + Placebo | Johnson & Johnson | Phase 3 | 40 |
| Quetiapine fumarate (Seroquel) SR | AstraZeneca | Phase 3 | 40 |
| Quetiapine fumarate (Seroquel) SR | AstraZeneca | Phase 3 | 40 |
| RO6889450 + Placebo + Risperidone | Roche | Phase 2 | 35 |
| RO6889450 + Placebo | Roche | Phase 2 | 27 |
| AMG 581 + Placebo + Midazolam | Amgen | Phase 1 | 29 |
| AMG 581 + Placebo | Amgen | Phase 1 | 29 |
| Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone + Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone | Pfizer | Phase 3 | 40 |
| Ziprasidone | Pfizer | Approved | 43 |
| ziprasidone | Pfizer | Pre-clinical | 26 |